Wong HH - Search Results

1

Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.

Wong HH, Barton C, Acton G, McLeod R, Halford S. Wong HH, et al. Eur J Cancer. 2016 Oct;66:9-16. doi: 10.1016/j.ejca.2016.07.004. Epub 2016 Aug 8. Eur J Cancer. 2016. PMID: 27514008 Review.

2

Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.

Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B. Ghorani E, et al. Among authors: wong hh. Oncology. 2015;89(5):281-7. doi: 10.1159/000439171. Epub 2015 Sep 16. Oncology. 2015. PMID: 26372905

3

Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?

Wong HH, Halford S. Wong HH, et al. Lancet Oncol. 2015 Oct;16(13):1287-8. doi: 10.1016/S1470-2045(15)00248-X. Lancet Oncol. 2015. PMID: 26433816 No abstract available.

4

Tivozanib for the treatment of metastatic renal cancer.

Wong HH, Eisen T. Wong HH, et al. Expert Rev Anticancer Ther. 2013 Jun;13(6):649-60. doi: 10.1586/era.13.40. Expert Rev Anticancer Ther. 2013. PMID: 23773100 Review.

5

Improving clinical trial recruitment: experience of a tertiary renal oncology centre.

Wong HH, Siegler C, Grainger S, Zaki KA, Matakidou A, Eisen T, Fife K. Wong HH, et al. Oncology. 2013;85(5):297-8. doi: 10.1159/000355688. Epub 2013 Nov 6. Oncology. 2013. PMID: 24217289 No abstract available.

6

Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma.

Doherty GJ, Davidson D, Wong HH, Hatcher HM. Doherty GJ, et al. Among authors: wong hh. Anticancer Drugs. 2019 Jan;30(1):110-115. doi: 10.1097/CAD.0000000000000693. Anticancer Drugs. 2019. PMID: 30540596

7

Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature.

Wong HH, Hatcher HM, Benson C, Al-Muderis O, Horan G, Fisher C, Earl HM, Judson I. Wong HH, et al. Clin Sarcoma Res. 2013 Nov 26;3(1):14. doi: 10.1186/2045-3329-3-14. Clin Sarcoma Res. 2013. PMID: 24280007 Free PMC article.

8

Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist's decision.

Wong HH, Collins J, McAdam K, Wilson C. Wong HH, et al. Oncology. 2014;86(1):22-3. doi: 10.1159/000356876. Epub 2013 Dec 10. Oncology. 2014. PMID: 24335099 No abstract available.

9

Pazopanib, a promising option for the treatment of aggressive fibromatosis.

Szucs Z, Messiou C, Wong HH, Hatcher H, Miah A, Zaidi S, van der Graaf WT, Judson I, Jones RL, Benson C. Szucs Z, et al. Among authors: wong hh. Anticancer Drugs. 2017 Apr;28(4):421-426. doi: 10.1097/CAD.0000000000000474. Anticancer Drugs. 2017. PMID: 28099210 Free PMC article.

10

Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib.

Wong HH, Bentley H, Bulusu VR, Anyaegbu G, Watkins J, Horan G, Hatcher H. Wong HH, et al. Anticancer Drugs. 2020 Nov;31(10):1106-1110. doi: 10.1097/CAD.0000000000000994. Anticancer Drugs. 2020. PMID: 32868646

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters